Alpha Cognition Inc. Company Profile
NASDAQ: ACOGHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
After hours: 9.04 0.00%
Alpha Cognition at a glance
Alpha Cognition Inc. (NASDAQ: ACOG) is a Biotechnology company in the Healthcare sector headquartered in Grapevine, TX, Canada. Alpha Cognition is led by Mr. Michael E. McFadden B.B.A. and employs about 71 people. At a market capitalization of $196.8 million, it is considered a small-cap company.
Its SEC Central Index Key (CIK) is 0001655923, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Alpha Cognition do?
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. Alpha Cognition Inc. was founded in 2000 and is headquartered in Grapevine, Texas.
Business description based on the company's public filings.
Company information
- Legal name
- Alpha Cognition Inc.
- Ticker
- NASDAQ: ACOG
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Michael E. McFadden B.B.A.
- Employees
- 71
- Headquarters
- 1452 Hughes Street, Grapevine, TX, Canada
- Phone
- 858 344 4375
- Website
- alphacognition.com
- Market cap
- $196.84M
- SEC CIK
- 0001655923